AbbVie Exercises Exclusive Option to License Argenx's ARGX-115
Shots:
- AbbVie will obtain a worldwide- exclusive license to develop and commercialize ARGX-115-based products
- Argenx to receive development- regulatory and commercial milestone payments of up to $625M- and has rights to co-promote ARGX-115 products in the EU and Swiss Economic Area
- Argenx and AbbVie previously entered into an option and license agreement for ARGX-115 in April 2016- for development and commercialization of ARGX-115
/ article | Ref: Argenx | Image: Cantilis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com